(Q24200189)

8

0 references

Kristian Thorlund

4

0 references

Tahany Awad

object named as

Tahany Awad

2

0 references

Goran Hauser

object named as

Goran Hauser

1

0 references

author name string

Jesper Brok

3

0 references

Davor Štimac

5

0 references

Mahasen Mabrouk

Cochrane Database of Systematic Reviews

6

0 references

publication date

28 February 2014

0 references

published in

0 references

cites work

Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Viral kinetics in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Effect of hepatitis C virus and its treatment on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Ribavirin plus interferon versus interferon for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Hepatitis C virus genotypes and quasispecies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Review article: pegylated interferons: chemical and clinical differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Hepatology may have problems with putative surrogate outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Pegylated-interferon-associated retinopathy in chronic hepatitis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Industry sponsorship and research outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Interferon for interferon naive patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Structural biology of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Neuropsychiatric adverse effects of interferon-alpha: recognition and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Recent advances in the molecular biology of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Arcsine test for publication bias in meta-analyses with binary outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

The history of the "natural history" of hepatitis C (1968-2009).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health an

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Estimating required information size by quantifying diversity in random-effects model meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Peginterferon vs. standard interferon in the treatment of chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005441.PUB3